Destination: The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer’s and related dementias.
Drug Development RFP: The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer’s and related dementias.
Neuroimaging and CSF Biomarker Development RFP: The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer’s disease and related dementias.
Prevention Pipeline RFP: The ADDF seeks to support studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.
Drug development: up to $600,000
Program to accelerate clinical trials : up to $3 million
Neuroimaging and CSF biomarker development program: up to $600,000
Prevention pipeline: up to $3 million for clinical trials
Drug development: 1 year, potential for follow-up funding.
Program to accelerate clinical trials: multi-year, potential for follow-up funding.
Neuroimaging and CSF biomarker development program: 1 year, potential for follow-up funding. Multi-year proposals can be considered.
Prevention pipeline: multi-year, potential for follow-up funding.
Fill out the form below to receive more information:
Collaborate with the IISPV and help us improve people's health through research!